Business Wire

CGTN

20.3.2021 13:19:10 CET | Business Wire | Press release

Share
CGTN: China Unveils New Discoveries From Sanxingdui, Over 500 Items Unearthed

Chinese archaeologists announced on Saturday that some new major discoveries have been made at the legendary Sanxingdui Ruins site in southwest China, helping shed light on the cultural origins of the Chinese nation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210320005008/en/

Archaeologists have found six new sacrificial pits and unearthed more than 500 items dating back about 3,000 years at the Sanxingdui Ruins in Sichuan Province, the National Cultural Heritage Administration (NCHA) announced in the provincial capital Chengdu.

Over 500 precious cultural relics discovered

Ranging from 3.5 to 19 square meters, these six sacrificial pits, which were discovered from November 2019 to May 2020, are in rectangular shape, according to NCHA. Among them, pits No.3, No.4, No.5 and No.6 have been excavated to the utensil layer so far, while pits No.7 and No.8 are being backfilled.

Together they form an area in which people of the ancient Shu civilization offered sacrifices to heaven, Earth and their ancestors, and prayed for prosperity and peace, according to Tang Fei, head of the excavation team at Sanxingdui and chief of the Sichuan Provincial Cultural Relics and Archaeology Research Institute.

The discoveries have shown the distinctiveness of the Shu civilization and the diversity of the Chinese civilization, said Ran Honglin, another researcher with the institute.

In addition, over 500 pieces of important cultural relics have been unearthed from these six pits, including the fragments of gold masks, bird-shaped gold ornaments, gold foil, painted bronze head portraits, giant bronze masks, bronze sacred tree, ivory, fragments of exquisite tooth carvings, jade cong and jade tools.

A gold mask has been unearthed at the No.5 sacrificial pit. With an area of about three square meters, it is the smallest pit, but it's where the most gold pieces were unearthed, according to archaeologists.

During the process, archaeologists have made full use of modern scientific and technological means to build an archaeological excavation cabin, integrated excavation platform and multi-functional excavation operation system.

With the support of professional teams of multiple disciplines and institutions, they have formed an integrated work mode combining traditional archaeology, laboratory archaeology, technological archaeology as well as the protection of cultural relics. The combination will ensure the high quality and high level of archaeological work, NCHA said at the conference.

Meanwhile, the NCHA has identified the "Research on the Civilization Process of Bashu in Sichuan-Chongqing Region" as a major program of the "Archaeological China" project, aiming to conduct in-depth study on the evolution of civilization in the region and its integration into the overall cultural landscape of the pluralistic unity of the Chinese nation.

Located in the city of Guanghan, some 40 kilometers from Sichuan's provincial capital Chengdu, the Sanxingdui Ruins site is regarded one of the most important archaeological discoveries in the 20th century. The excavation has lasted for nearly 100 years since the first discovery in the late 1920s.

In 1986, archaeologists found two large-scale sacrificial pits dating back to the Shang Dynasty (1600-1046 BC). Thousands of rare treasures were discovered from the two pits.

https://news.cgtn.com/news/2021-03-20/China-unveils-new-discoveries-from-Sanxingdui-YMkx9az0Yg/index.html

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release

Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604

Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release

Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release

Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye